OTCMKTS:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis $0.0004 0.00 (0.00%) (As of 10/29/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About Propanc Biopharma Stock (OTCMKTS:PPCB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Propanc Biopharma alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000450-Day Range N/A52-Week Range$0.00▼$0.02Volume2.58 million shsAverage Volume13.47 million shsMarket Capitalization$251,645.10P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address PPCB Stock News HeadlinesPropanc Biopharma Inc (PPCB)August 21, 2024 | investing.comPropanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North AmericaAugust 14, 2024 | finance.yahoo.comThe most productive 1 min of your day… This next step in your trading career is a simple, yet important one. I want you to take 1 minute to sign up for FREE algo alerts powered by StocksToTrade.October 30, 2024 | Timothy Sykes (Ad)VTXB Vortex Brands Co.May 29, 2024 | seekingalpha.comPropanc Biopharma, Inc. (PPCB)May 29, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent OfficeApril 16, 2024 | finance.yahoo.comPropanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 10, 2024 | stockhouse.comPropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 8, 2024 | finance.yahoo.comSee More Headlines PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed this year? Propanc Biopharma's stock was trading at $0.0120 at the beginning of 2024. Since then, PPCB shares have decreased by 97.1% and is now trading at $0.0004. View the best growth stocks for 2024 here. When did Propanc Biopharma's stock split? Propanc Biopharma shares reverse split on the morning of Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH). Company Calendar Today10/29/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PPCB CUSIPN/A CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,368.98% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-0.04Miscellaneous Outstanding Shares718,990,000Free Float718,267,000Market Cap$251,646.50 OptionableNot Optionable Beta1.99 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (OTCMKTS:PPCB) was last updated on 10/30/2024 by MarketBeat.com Staff From Our PartnersThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredThis biotech's ONE drug could change medicine as we know itThis Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses...Smallcaps Daily | Sponsored2 Pro Traders… 4 Livestreams… 4 Live TradesThe Zero Day Loophole: The Secret of HUGE Overnight Profits from Government ReportsMonument Traders Alliance | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredIs your portfolio prepared for AI 2.0?AI has exploded ever since ChatGPT set the world on fire near the end of 2022. Numerous companies with conn...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.